Click here to view online. Add this email to your safelist.
AstraZeneca expands global footprint in rare disease with availability of first Alexion rare disease therapy for patients in China
11 November 2022
AstraZeneca today announced the availability of the first rare disease therapy from Alexion, AstraZeneca’s Rare Disease group, in China. The availability of Soliris (eculizumab) for the treatment of paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS) in adults and children in China represents a significant expansion of the company’s global footprint in rare disease, following the acquisition of Alexion Pharmaceuticals, Inc. in 2021.
|
|||||
|
|||||
|
For more information please visit astrazeneca.com. If you would like to unsubscribe please click here. |
